During the past decade, Del-pesti Centrumkorhaz - Orszagos Hematologiai es Infektologiai Intezet conducted 57 clinical trials. In the 10-year time frame, 57 clinical trials started and 29 clinical trials were completed, i.e. on average, 50.9% percent of trials that started reached the finish line to date. In the past 5 years, 33 clinical trials started and 18 clinical trials were completed. i.e. 54.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Del-pesti Centrumkorhaz - Orszagos Hematologiai es Infektologiai Intezet" #1 sponsor was "Pfizer" with 9 trials, followed by "Janssen Research & Development, LLC" with 8 trials sponsored, "Eli Lilly and Company" with 6 trials sponsored, "Amgen" with 4 trials sponsored and "Galapagos NV" with 4 trials sponsored. Other sponsors include 41 different institutions and companies that sponsored additional 42 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Del-pesti Centrumkorhaz - Orszagos Hematologiai es Infektologiai Intezet" #1 collaborator was "Eli Lilly and Company" with 3 trials as a collaborator, "Gilead Sciences" with 3 trials as a collaborator, "ICON plc" with 2 trials as a collaborator, "Incyte Corporation" with 2 trials as a collaborator and "Millennium Pharmaceuticals, Inc." with 2 trials as a collaborator. Other collaborators include 16 different institutions and companies that were collaborators in the rest 24 trials.

According to Clinical.Site data, the most researched conditions in "Del-pesti Centrumkorhaz - Orszagos Hematologiai es Infektologiai Intezet" are "Multiple Myeloma" (5 trials), "Systemic Lupus Erythematosus" (4 trials), "Gastric Cancer" (3 trials), "Ulcerative Colitis" (3 trials) and "Cardiovascular Disease" (2 trials). Many other conditions were trialed in "Del-pesti Centrumkorhaz - Orszagos Hematologiai es Infektologiai Intezet" in a lesser frequency.

Most popular intervention types in "Del-pesti Centrumkorhaz - Orszagos Hematologiai es Infektologiai Intezet" are "Drug" (73 trials), "Other" (9 trials), "Biological" (5 trials), "Combination Product" (1 trials) and "Genetic" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (34 trials), "Filgotinib" (5 trials), "Lenalidomide" (5 trials), "Rituximab" (5 trials) and "Bortezomib" (4 trials). Other intervention names were less common.

The vast majority of trials in "Del-pesti Centrumkorhaz - Orszagos Hematologiai es Infektologiai Intezet" are 75 trials for "All" genders, 1 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Del-pesti Centrumkorhaz - Orszagos Hematologiai es Infektologiai Intezet". undefined are not yet recruiting, 26 are recruiting, 8 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 25 completed trials in Del-pesti Centrumkorhaz - Orszagos Hematologiai es Infektologiai Intezet, undefined suspended trials, and 14 terminated clinical trials to date.

Out of the total trials that were conducted in Del-pesti Centrumkorhaz - Orszagos Hematologiai es Infektologiai Intezet, 0 "Phase 1" clinical trials were conducted, 14 "Phase 2" clinical trials and 64 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".